Beta Blockers for Peripheral Arterial Disease  by Paravastu, S.C.V. et al.
Eur J Vasc Endovasc Surg (2009) 38, 66e70Beta Blockers for Peripheral Arterial Disease*S.C.V. Paravastu a,1, D.A. Mendonca b,2, A. da Silva c,*a Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
b 8 Manor House Close, Bescot, Walsall WS1 4PB, UK
c Wrexham Maelor Hospital, Croesnewydd Road, Wrexham LL13 7TD, UK
Submitted 10 February 2009; accepted 15 February 2009
Available online 9 April 2009KEYWORDS
Beta blockers;
Peripheral vascular
disease;
Intermittent
claudication* This work was presented at the 2
national Society of Vascular Surgery,
* Correspondingauthor.Tel.:þ441978
E-mail addresses: sharathpa
(S.C.V. Paravastu), derickmen@ya
tony.dasilva@new-tr.wales.nhs.uk (A.
1 Tel.: þ44 161 276 4525; fax: þ44 1
2 Tel.: þ44 7876747695.
1078-5884/$36 ª 2009 European Socie
doi:10.1016/j.ejvs.2009.02.019Abstract Objectives: To quantify the potential harm of beta blockers in patients with periph-
eral arterial disease.
Materials and methods: All randomised controlled trials (RCTs) comparing beta blockers with
placebo for the outcomes of claudication andmaximal walking distance and time, calf blood flow,
vascular resistance and skin temperature were searched using the Cochrane Controlled Trials
Register, PubMed and CINAHL. Trials comparing different types of beta blockers were excluded.
Results: Six RCTs fulfilling the above criteria, with a total of 119 patients, were included. The beta
blockers studied were atenolol, propranolol, pindolol and metoprolol. None of the trials showed
a statistically significantworsening effect of beta blockers on the outcomesmeasured. Therewere
no reports of any adverse events with the beta blockers studied.
Conclusions: Currently, there is noevidence to suggest that beta blockers adversely affectwalking
distance inpeoplewith intermittentclaudication.Betablockers shouldbeusedwith caution if clin-
ically indicated, especially in patients with critical ischaemia where acute lowering of blood pres-
sure is contraindicated.
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ty for Vascular Surgery. PublisheIntermittent claudication is the most common symptom of
atherosclerotic peripheral arterial disease (PAD)1 and
reflects decreased blood flow to the extremities during
exercise.2 The incidence of intermittent claudication
increases with advancing age, cigarette smoking, impaired
glucose tolerance and hypertension.3 Men are twice as
likely as women to be affected by intermittent claudica-
tion.4 Patients with PAD have increased rates of mortality
because of concurrent coronary artery disease and
hypertension.5
Beta (b) blockers have been shown to decrease mortality
in people with hypertension and coronary artery disease.d by Elsevier Ltd. All rights reserved.
Beta Blockers 67Besides being used primarily for their cardiovascular effects
to treat arrhythmias (variations in the normal rhythm of the
heart beat), b blockers are also used to treat migraine
headaches, essential tremors, thyrotoxicosis (excessive
production of thyroid hormones), glaucoma, anxiety and
various other disorders. b Blockers are a large group of
drugs and although all are competitive inhibitors of
b receptors, they may have additional pharmacodynamic
properties. In addition to increasing the force and rate of
myocardial contraction, b1 receptors also increase the
conduction velocity through the atrioventricular (AV) node.
Therefore, b1 blockade reduces heart rate, blood pressure,
myocardial contractility and myocardial oxygen consump-
tion. A b2 receptor blockade inhibits relaxation of smooth
muscle in blood vessels, bronchi and the gastrointestinal
and genitourinary tracts. In addition, b2 blockade inhibits
the breakdown of glycogen (the main carbohydrate storage
compound) to glucose (glycogenolysis) and the formation of
sugar from protein and fat in the absence of glucose or
carbohydrate (gluconeogenesis). Non-specific b blockers
such as propranolol, timolol, nadolol and pindolol demon-
strate equal affinity for both b1 and b2 receptors.
Commonly used cardioselective (b1) blockers are atenolol
and metoprolol.
In general, the blockade of b receptors results in
a decreased production of intracellular cyclic adenosine
monophosphate (cAMP), with a resultant blunting of the
multiple metabolic and cardiovascular effects of circulating
catecholamines. b Blockers are prescribed for use after
myocardial infarction (MI). It has been shown that therapy
initiated within 12 h of MI decreases the rate of in-hospital
cardiovascular mortality by 13e15%.6 b Blockers have also
been prescribed for use in patients with continuing or
recurrent ischaemic pain, tachyarrhythmias (rapid heart
rates associated with an irregularity in the normal heart
rhythm) as well as with non-ST-elevation MI.7
Optimal therapy for either coronary artery disease or
hypertension accompanied by intermittent claudication has
been controversial due to presumed peripheral haemody-
namic consequences of b blockers that could lead to
worsening of the symptoms in patients with PAD.8 This has
been attributed to the decreased cardiac output and
unopposed alpha (a) adrenergic drive.
It is well known that acute lowering of blood pressure is
contraindicated in critical ischaemia. However, the effect
of lowering of blood pressure in people with intermittent
claudication is not known. b Blockers are contraindicated in
severe PAD.9 The aim of this review is to determine the
evidence for the contraindication of b blockers in people
with intermittent claudication.
Methods
Inclusion criteria
The study included randomised controlled trials (RCTs)
comparing b blockers and placebo in patients with PAD.
Patients with moderate-to-severe PAD, with or without
additional co-morbidity (an additional disease or condition
for example, diabetes mellitus), were included. PAD was
defined as a typical history of intermittent claudicationand reduced ankleebrachial pressure index (ABPI), less
than 0.9. We included studies using selective b blockers
(b1) and non-selective b blockers (b1 and b2), whereas we
excluded some b blockers with additional a blocking
properties.
Types of outcome measures
Primary outcomes
In this study, primary outcome measures considered were
initial claudication distance in metres, and the time to
claudication in minutes and maximal walking distance in
metres and minutes (as assessed by treadmill).
Secondary outcomes
Secondary outcome measures included calf blood flow
(ml1 100 ml min1), calf vascular resistance and skin
temperature (C). Mortality data; complications of
b blockers, such as development of critical ischaemia,
cardiovascular morbidity and mortality; all-cause mortality
and drug withdrawal were also recorded in participants
with stable PAD.
Search strategy
The Cochrane Peripheral Vascular Diseases (PVD) Group
searched their Trials Register (last searched 6 May, 2008)
and the Cochrane Central Register of Controlled Trials
(CENTRAL) (last searched The Cochrane Library 2008, Issue
2) for publications describing RCTs of b blockers in PAD. The
PVD Group Trials Register has been compiled from elec-
tronic searches of MEDLINE (1966 to date), EMBASE (1980 to
date) and CINAHL (1982 to date); and through a manual
search of relevant journals and conference proceedings.
We searched bibliographies of all identified articles, review
articles and major vascular textbooks. There were no
restrictions on language of publication.
Data collection and analysis
Selection of trials
All three review authors independently reviewed the
abstracts of potential trials involving b blockers in PAD. We
obtained full papers for those fulfilling the relevant criteria
or where clarification was required. We excluded trials
comparing different types of b blockers (Fig. 1).
Quality of trials
All three review authors independently assessed the
methodological quality of selected trials using the methods
described by Jadad et al.10 and Schulz et al.11 These scales
were not used to exclude potential trials but to explore
potential heterogeneity of method and quality.
Data extraction
All three review authors independently extracted data
using the proforma designed by the Cochrane PVD Group.
Some of the results were presented only as graphs and
hence we excluded them. Vascular resistance is described
in arbitrary units. The authors calculated vascular resis-
tance by dividing mean arterial blood pressure with calf
blood flow.
Figure 1 Flow chart for selection of studies.
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As there were insufficient data from the included studies,
we did not perform a meta-analysis.
Description of studies
We included six RCTs that fulfilled the inclusion criteria
(Clement 1980; Hiatt 1985; Lepantalo 1984a; Lepantalo
1985; Roberts 1987; Solomon 1991).
Various b blockers were used and compared with
placebo in the above-mentioned trials. Propranolol, ate-
nolol and metoprolol were the most commonly evaluated
b blockers.
In a randomised, double-blind, placebo-controlled trial,
Clement12 evaluated the effect of propranolol (80 mg twice
daily) and metoprolol (100 mg twice daily) on claudication
and maximal walking times in patients with chronic inter-
mittent claudication. In this cross-over trial, 10 patients
with chronic intermittent claudication were given
a washout period with placebo for 4 weeks and were
subsequently randomised to receive metoprolol, propran-
olol or placebo for 2 months each.
Lepantalo13 studied the effects of metoprolol and
methyldopa on calf blood flow and vascular resistance in
patients with peripheral vascular disease. In this rando-
mised, double-blind, placebo-controlled trial, 14 patients
were given placebo in the run-in phase for 3 weeks and
were subsequently randomised to receive either metoprolol
(100e200 mg), methyldopa (500e1000 mg) or a placebo for
3 weeks each. Calf blood flow was measured using venous
occlusion plethysmography. In another randomised, double-
blind placebo-controlled trial, Lepantalo14 evaluated the
effects of propranolol (80 mg), pindolol (5 mg), labetalol
(200 mg), labetalol (400 mg) and placebo on hyperaemic
calf blood flow, skin temperature and vascular resistance inseven patients with hypertension and chronic intermittent
claudication. All drugs were administered for 10 days each.
Hiatt et al.15 compared the effects of metoprolol
(50 mg) and propranolol (40 mg) with placebo on calf blood
flow and vascular resistance. In this randomised, double-
blind, placebo-controlled trial, 19 patients with chronic
stable intermittent claudication received placebo in the
run-in phase for 3 weeks. Participants were later rando-
mised to receive either metoprolol or propranolol for
2 weeks. Subsequently, they were administered placebo for
2 weeks before the cross-over phase. Calf blood flow was
measured using venous occlusion plethysmography.
Roberts et al.16 administered atenolol (100 mg), labe-
talol (200 mg), pindolol (5 mg), captopril (25 mg) and
placebo to a total of 20 patients and studied their effects
on mean blood pressure, calf blood flow, mean pain-free
walking distance and mean maximal walking distance. All
the patients received placebo for a month as an initial
washout phase. Later, they were randomised to receive
atenolol, labetalol, pindolol, captopril or placebo for
1 month each. Calf blood flow was measured using venous
occlusion plethysmography and walking distances using
a treadmill.
Solomon et al.17 evaluated the effect of atenolol
(50 mg), nifedipine (20 mg) e a combination of atenolol and
nifedipine e and placebo on skin temperature and walking
distance in a total of 49 patients. Patients were randomised
after a run-in phase with placebo. In this cross-over trial,
drugs were administered for 4 weeks each. There was no
washout period before cross-over of patients.
Results
None of the primary outcomes was reported by more than
one study. Similarly, secondary outcome measures, with
Beta Blockers 69the exception of vascular resistance (reported by three
studies), were reported by one study each. Pooling of such
results was, therefore, deemed inappropriate and hence
results of individual series were presented.
Claudication time
One trial evaluated claudication time.12 In this study,
propranolol and metoprolol were compared with placebo.
The mean claudication times were 5.20 min (standard devi-
ation (SD) 2.25), 4.90 min (SD 2.04) and 4.53 min (SD 1.43)
with propranolol, metoprolol and placebo, respectively.
Maximum walking time
Propranolol and metoprolol were compared with placebo.12
The mean maximal walking times were 8.18 min (SD 2.54),
8.18 min (SD 2.47) and 7.75 min (SD 2.20) with propranolol,
metoprolol and placebo, respectively.
Claudication distance
Only one trial evaluated claudication distance, comparing
atenolol with placebo.17 The mean claudication distance
was 62.6 m for those who received atenolol in comparison
to 66.5 m for those in the placebo group. The author
reported a mean change reduction of 6% (95% confidence
interval (CI) 1e13%) which was not considered to be clini-
cally or statistically significant.
Maximum walking distance
Solomon et al. evaluated maximum walking distance,
comparing atenolol with placebo. The maximum walking
distances with atenolol and placebo were 110.8 m and
113.8 m, respectively. The authors reported a mean change
reduction of 2% (95% confidence interval (CI): 4e8%), which
was not considered to be clinically or statistically
significant.
Calf blood flow after exercise
Roberts et al. compared the effects of atenolol and pindolol
with placebo on calf blood flow after exercise. The mean
calf blood flow after exercise was 25.5 (SD 15.6), 20.1 (SD
10.2) and 29.9 (SD 17.8) ml dl1 min1 with atenolol, pin-
dolol and placebo, respectively.
Skin temperature
The effect of propranolol and pindolol on skin temperature
was evaluated in one trial.14 The mean skin temperature
was 24.9 C (SD 3.8), 25.5 C (SD 4.0) and 27 C (SD 4.1) with
propranolol, pindolol and placebo, respectively.
Vascular resistance
The effects of propranolol and pindolol versus placebo on
vascular resistance after reactive hyperaemia were evalu-
ated in one trial.14 The vascular resistance was 2.5 units (SD
1.2), 2.1 units (SD 1.3) and 2.1 units (SD 1.3) withpropranolol, pindolol and placebo, respectively. The effect
of metoprolol on calf vascular resistance was evaluated by
Lepantalo.13 The results showed the vascular resistance to
be 1.7 units (SD 0.9) with metoprolol and 1.5 units (SD 1.0)
with placebo.
Hiatt et al. also compared the effect of metoprolol on
vascular resistance after exercise. Vascular resistance was
11.5 units (SD 4.7) and 11.2 units (SD 4.4) for metoprolol
and placebo, respectively.
Adverse events
In all the trials we reviewed, there were no reports of any
adverse events related to the use of b blockers. The trials
also did not report any issues regarding patient compliance
with medication.
Discussion
This systematic review identified six randomised, double-
blind, placebo-controlled, cross-over trials with a total of
119 patients. Most were small trials recruiting between 10
and 20 participants, with the largest study enrolling 49
participants.17
None of the trials showed a statistically significant
worsening effect for b blockers on either the primary or
secondary outcomes in participants with claudication. All
trials were of poor quality, with the drugs being adminis-
tered for a short period of time (10 dayse2 months).
The trial by Clement12 using propranolol did not
demonstrate a statistically significant decrease for either
claudication time or maximum walking time. This was
a small trial including only 10 patients. Details and data
regarding the cross-over phase were unclear.
Lepantalo13 studied the effects of metoprolol on calf
blood flow and vascular resistance. The results did not show
any deleterious effects in themetoprolol group. In this cross-
over trial, participants were also randomised to receive
methyldopa, further confounding the results of this study.
In another study, Lepantalo14 randomised a small number
of patients to receive placebo, propranolol, pindolol and
different strengths of labetalol (200 mg and 400 mg). The
results, as described above, showed no statistically signifi-
cant worsening effects on the studied outcome measures.
This small group of participants lacked proper randomisation
and an unclear cross-over phase, further raising questions
about the validity of its conclusions.
The overall effect of atenolol on claudication and
maximal walking distances could not be estimated due to
the lack of sufficient data. In the trial by Solomon et al.,17
nifedipine (a calcium channel blocker) was used as an
additional drug in one of the drug groups, however, there
was no washout period before the cross-over phase. In
addition, this is bound to have affected the outcome
measures, which may not truly represent the effects of
each individual drug.
This study is not without a few limitations that are
worthy of note. Most of the trials were over 10 years of age
and none of them supplied any power calculations or a valid
method of randomisation. Most importantly, there was no
consistency in the inclusion criteria between trials and
70 S.C.V. Paravastu et al.most of the included patients suffered from either mild or
moderate PVD. The duration of the course of b blockers and
the cross-over phases varied between trials, with no
washout periods in some trials. In other trials, calcium
channel blockers and combined a and b blockers were used.
Furthermore, primary outcome measures were available in
only two trials, with complete outcome data lacking in one
of them. Finally, there were not enough data to pool indi-
vidual results, hence individual data are presented. In
conclusion, despite the inclusion of six randomised trials
the evidence either supporting or against the use of
b blockers in PAD remains elusive.
Conclusion
Currently, there is no evidence to suggest that b blockers
adversely affect walking distance in people with intermit-
tent claudication. This has practical implications, as in the
current scenario b blockers play a significant role in
averting major cardiovascular and perioperative complica-
tions. However, b blockers should be used with caution if
clinically indicated, especially in patients with critical
ischaemia where acute lowering of blood pressure is
contraindicated.
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